Subscribe to receive this FREE daily commentary directly in your email
[widget id=”text-22″]
Acadia, Biogen, Celgene, Regeneron In Focus – A Look At The Week Ahead
The stock market will look to build on last weeks gains, and it will be a week filled with economic data and Fed talk.
The one segment of the market rally that has been missing has been the biotech sector, and it is no wonder when stocks like Celgene, Biogen, and Regeneron have been in the gutter. Acadia gets a shot at breaking the negative news cycle this week and perhaps giving the group a boost.
[widget id=”text-16″]
Economic Outlook
Fed Chair Powell will speak to the House on Tuesday starting at 10 am while talking to the Senate on Thursday at 10 am. Fourth quarter GDP will come on Wednesday, and the consensus is looking for a reading of 2.5 percent. But the significant reading will occur on Thursday when we get Personal Income and Outlays. Personal Income is expected to have a reading of 0.3%, while PCE is expected to show a y/y gain of 1.7 percent, while core y/y is supposed to rise by 1.5 percent.
[widget id=”text-19″]
Biotech
Biotech has been a weak group, and the internals for the leadership is nothing to write home about. Shares of Celgene, Biogen, and Regeneron have fallen on hard times, with these three stocks accounting for nearly 25 percent of the Nasdaq Biotech ETF (IBB) it is hard to imagine the group can advance much without them.
[widget id=”text-21″]
Celgene
Celgene shares have seen a disastrous fall from grace, shares have fallen by an astounding 35 percent from a high near $147 to almost $95.50. The company has made a number of moves to help bolster the pipeline and calm nerves around the dependence on Revlimid, recently announcing it would buy Juno, but still, shares have suffered. Admittedly, this one has gone against me, and I’m not thrilled with the outcome.
The good news is that the stock has managed to hold support around $94. The bad news is that every time it has shown a sign of life over the past few months the stock just goes the other way.
Despite the recent acquisitions, analysts have yet to up their revenue targets, remaining reasonably flat, while trading at Gilead type of valuations of 9.3 times 2019 earnings estimate of $10.22.
CELG Revenue Estimates for Current Fiscal Year data by YCharts
[widget id=”wordads_sidebar_widget-41″]
Biogen
Biogen shares are in the same camp, having fallen from nearly $370 to $283, a decline of 23 percent. On February 7, the company announced it would stop developing Tysabri to treat acute ischemic stroke patients. Then adding insult to injury, one week later the company announced it would be adding patients to its trial in Alzheimer’s disease drug for aducanumab, creating more fear.
The chart like Celgene shows the stock has gotten to critical support to $282. It had seemed for some time that Biogen was destined to reach $400, but the negative news flow has just changed that direction.
[widget id=”text-23″]
Regeneron
Regeneron shares have broken down, and what had been a failed breakout attempt, now puts shares in of danger of heading lower to $273.
[widget id=”wordads_sidebar_widget-41″]
Acadia
Acadia will post fourth-quarter results on Tuesday. Analysts are looking for the company to report that revenue climbed by over 275 percent in the fourth quarter to $45.18 million, on a loss of $0.57. More important will be any commentary on 2018 guidance, where analysts are looking for revenue of $253 million.
When looking at the current run rate of quarterly revenue growth, we can see the growth has been relatively linear. Should revenue come in at analysts estimates or higher, it would continue to put the company on pace to have revenue of $300 million in 2018, about $50 million more than expectations, but we will surely find out more details
The stock has been a bust for years now, and it seems that every piece of positive news has been met with selling pressure.
Will something change soon? Hopefully, but at this point frustration with this stock runs deep. It feels as though every time I think the stock is about to breakout, it fails. My expectations for revenue growth are solid when it comes to the quarter and next year. But when it comes to how the stock will perform, I at a loss, and tired of guessing, getting my hopes to only be met with disappointment.
If the fundamentals continue to improve, one has to believe one day it will be reflected in the stock price.
Good luck his week.
[widget id=”text-12″]
Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets
Just $200 Per Year – Get Your Free 2 Week Trial
Recent Videos:
Stock Market Still Not Out Of Danger Zone
Crazy Market Reaction Following Fed Minutes, Plus Subscriber Mail Bag
Subscriber Mailbag, Plus Market Rundown
Why Amazon Has Peaked And Tesla Could Be Cheap
Inflation Rising, Rates Rising, Stocks Do Not Care!
Stock Price Continue To Rebound, More To Come?
Free Articles Written By Mike:
AMD Analysts See 20% Stock Gain Despite Red Flags
PayPal Seen Falling 15% on Loss of Biggest Customer
How Costco’s Stock Can Soar On E-Commerce
Roku’s Stock May Fall 35% Further As Sales Stall
3 Commodity Stocks That May Soar 20% on Inflation
Why Walmart Will Never Be Amazon
eBay’s Lagging Stock Set To Rise On Revenue Growth
Biotech Alkermes May Surge On Wave of New Drugs
Apple Options Traders Bet Big On 15% Share Gain
Why Chip Stocks Are Still Cheap
Disney’s Stock Looks Like a Bargain
Chipotle’s Stock Rebound May Fizzle
Why Facebook’s Rally Is Lagging the Techs
Join our 2,618 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
-OR-
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]
Michael Kramer and the Clients of Mott Capial own shares of CELG and ACAD
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2018 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Tags: #sp500 #stocks #biotech #celgene #acadia #regeneron #biogen
Subscribe to receive this FREE daily commentary directly in your email
Charts used with the permission of Bloomberg Finance L.P. This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.
Rates Surge Stocks Drop Following Hot Job Report, CPI Next Week
Mott Capital's Market Chronicles January 10, 2025 12:02 PM